2021
COVID-19 Outcomes and Genomic Characterization of SARS-CoV-2 Isolated From Veterans in New England States: Retrospective Analysis
Lee M, Sallah YH, Petrone M, Ringer M, Cosentino D, Vogels CBF, Fauver JR, Alpert TD, Grubaugh ND, Gupta S. COVID-19 Outcomes and Genomic Characterization of SARS-CoV-2 Isolated From Veterans in New England States: Retrospective Analysis. JMIRx Med 2021, 2: e31503. PMID: 35014989, PMCID: PMC8722526, DOI: 10.2196/31503.Peer-Reviewed Original ResearchSARS-CoV-2 infectionPeak disease severityCOVID-19 outcomesChart reviewMean ageDisease severityHigher comorbidity burdenRetrospective chart reviewSARS-CoV-2 RNACohort of veteransGeneral US populationNon-white raceCOVID-19 infectionManual chart reviewSARS-CoV-2Multivariate regression analysisO2 requirementsNon-white veteransSARS-CoV-2 lineagesComorbidity burdenVirologic factorsD614G substitutionMultiple SARS-CoV-2 lineagesVirologic characteristicsClinical outcomesDelayed production of neutralizing antibodies correlates with fatal COVID-19
Lucas C, Klein J, Sundaram ME, Liu F, Wong P, Silva J, Mao T, Oh JE, Mohanty S, Huang J, Tokuyama M, Lu P, Venkataraman A, Park A, Israelow B, Vogels CBF, Muenker MC, Chang CH, Casanovas-Massana A, Moore AJ, Zell J, Fournier JB, Wyllie A, Campbell M, Lee A, Chun H, Grubaugh N, Schulz W, Farhadian S, Dela Cruz C, Ring A, Shaw A, Wisnewski A, Yildirim I, Ko A, Omer S, Iwasaki A. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nature Medicine 2021, 27: 1178-1186. PMID: 33953384, PMCID: PMC8785364, DOI: 10.1038/s41591-021-01355-0.Peer-Reviewed Original ResearchConceptsDeceased patientsAntibody levelsAntibody responseDisease severityAnti-S IgG levelsCOVID-19 disease outcomesFatal COVID-19Impaired viral controlWorse clinical progressionWorse disease severitySevere COVID-19Length of hospitalizationImmunoglobulin G levelsHumoral immune responseCoronavirus disease 2019COVID-19 mortalityCOVID-19Domain (RBD) IgGSeroconversion kineticsDisease courseIgG levelsClinical parametersClinical progressionHumoral responseDisease onset
2016
Ebola Virus Glycoprotein with Increased Infectivity Dominated the 2013–2016 Epidemic
Diehl WE, Lin AE, Grubaugh ND, Carvalho LM, Kim K, Kyawe PP, McCauley SM, Donnard E, Kucukural A, McDonel P, Schaffner SF, Garber M, Rambaut A, Andersen KG, Sabeti PC, Luban J. Ebola Virus Glycoprotein with Increased Infectivity Dominated the 2013–2016 Epidemic. Cell 2016, 167: 1088-1098.e6. PMID: 27814506, PMCID: PMC5115602, DOI: 10.1016/j.cell.2016.10.014.Peer-Reviewed Original ResearchMeSH KeywordsAfrica, WesternAmino Acid SubstitutionAnimalsCallithrixCarrier ProteinsCheirogaleidaeCytoplasmEbolavirusHemorrhagic Fever, EbolaHumansIntracellular Signaling Peptides and ProteinsMembrane GlycoproteinsNiemann-Pick C1 ProteinProtein Conformation, alpha-HelicalViral Envelope ProteinsVirionVirulenceConceptsHuman dendritic cellsIncreased infectivityEbola virus disease epidemicHuman hostEbola virus glycoproteinDendritic cellsHuman transmission eventsEVD epidemicEBOV-GPDisease severityViral mutationsViral infectivityPrimate cellsIntrinsic infectivityTransmission eventsInfectivityEpidemicVirus glycoproteinDisease epidemicsCellsNonsynonymous mutationsMutationsOutbreakHigh frequencyMortality